Current Hypertension Reports

, Volume 14, Issue 6, pp 603–607 | Cite as

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?

Pediatric Hypertension (JT Flynn, Section Editor)


There has been an evolution in the understanding of the treatment of hypertension in children and adolescents over the past decade. This has been fueled in part by the increased attention paid to the clinical problem, given the increasing numbers of children and adolescents being diagnosed with this condition. There has also been a growing number of clinical trials performed and completed that demonstrate the blood pressure (BP)-lowering effects of antihypertensives and the side effect profiles of these medications, and that has led to FDA-labeling of many antihypertensive medications for use in children and adolescents. However, none of these trials has provided definitive data on the optimal first line agent for this patient population. Clinical experience and other approaches discussed in this review are still necessary to guide treatment of hypertension in the young. The quest for the optimal antihypertensive agent is just beginning, and it is going to take some extraordinary effort to reach that goal.


Hypertension Blood pressure Pediatric Children Adolescents Antihypertensive medication Treatment 



D. Batisky: research funding from Novartis and Takeda (NIH R01HL098332-01A1).


Papers of particular importance, published recently, have been highlighted as: •• Of major importance

  1. 1.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.CrossRefGoogle Scholar
  2. 2.
    Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–42.PubMedCrossRefGoogle Scholar
  3. 3.
    •• The Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report, Pediatrics 2011, 128 (Supplement 5): S213–S256. Updated, comprehensive cardiovascular risk reduction guidelines; hypertension section similar to the Fourth Report. Google Scholar
  4. 4.
    Feber J, Ahmed M. Hypertension in children: new trends and challenges. Clin Sci. 2010;119:151–61.PubMedCrossRefGoogle Scholar
  5. 5.
    Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol. 2005;20:791–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Podoll A, Grenier M, Croix B, Feig DI. Inaccuracy in pediatric outpatient blood pressure measurement. Pediatrics. 2007;119:e538–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Stewart JN, McGillivray D, Sussman J, Foster B. The value of routine blood pressure measurement in children presenting to the emergency department with nonurgent problems. J Pediatr. 2008;153:478–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Lande MB, Flynn JT. Treatment of hypertension in children and adolescents. Pediatr Nephrol. 2009;24:1939–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Batisky DL. Obesity and the role of lifestyle and dietary intervention in the management of pediatric hypertension. J Med Liban. 2010;58:171–4.PubMedGoogle Scholar
  10. 10.
    Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24:1101–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Flynn JT. Pediatric hypertension: recent trends and accomplishments, future challenges. Am J Hypertens. 2008;21:605–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Flynn JT, Falkner BE. Obesity hypertension in adolescents: epidemiology, evaluation, and management. J Clin Hypertens. 2011;13:323–31.CrossRefGoogle Scholar
  13. 13.
    Batisky DL. Blood pressure variability, prehypertension, and hypertension in adolescents. Adolesc Health, Med Ther. 2012;3:1–8.Google Scholar
  14. 14.
    Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA. 2003;289:2560–72.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484–90. Only recent clinical trial in pediatric hypertension comparing two different classes of agents. PubMedCrossRefGoogle Scholar
  16. 16.
    Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiologic parameters. Med Hypoth. 2010;75:439–41.CrossRefGoogle Scholar
  17. 17.
    Laragh JH. Abstract, closing summary, and table of contents for Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens. 2001;14:1173–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Laragh JH, Sealey JE. The Plasma Renin Test Reveals the Contribution of Body Sodium-Volume Content (V) and Renin-Angiotensin (R) Vasoconstriction to Long-Term Blood Pressure. Am J Hypertens. 2011;24:1164–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Flynn JT. Management of hypertension in the young: role of antihypertensive medications. J Cardiovasc Pharmacol. 2011;58:111–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5:330–55.CrossRefGoogle Scholar
  21. 21.
    Flynn JT, Newburger JW, Daniels SW, et al. for the PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145:353–9.PubMedCrossRefGoogle Scholar
  22. 22.
    •• Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens. 2012;14:383–7. This reference is a concise, well-organized, and current review of this topic. CrossRefGoogle Scholar
  23. 23.
    Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens. 2007;20:990–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Wühl E, Mehls O, Schaefer F, ESCAPE Trial Group. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int. 2004;66:768–76.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Anti-hypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens. 2012;14:388–95. Demonstrates ongoing use of antihypertensive medications despite lack of FDA-approved pediatric labeling. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of PediatricsEmory University School of MedicineAtlantaUSA
  2. 2.Pediatric Hypertension ProgramChildren’s Healthcare of AtlantaAtlantaUSA
  3. 3.Emory-Children’s CenterAtlantaUSA

Personalised recommendations